TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30892820

Group type: EXPERIMENTAL
Intervention: NAFLD defined using a liver‐spleen ratio (L/S ratio) ≤1.1 on unenhanced abdominal CT scanning
Number of subjects: 4002

Group type: EXPERIMENTAL
Intervention: Higher body mass index, waist circumference, serum triglyceride, alanine transaminase, and hemoglobin A1c
Number of subjects: 4002

Group type: EXPERIMENTAL
Intervention: Higher annual household income and systolic blood pressure for men
Number of subjects: 4002

Group type: EXPERIMENTAL
Intervention: Higher serum uric acid and red meat intake and lower physical activity levels for women
Number of subjects: 4002

Group type: EXPERIMENTAL
Intervention: L/S ratio ≤1.1
Number of subjects: 4002
Study: 30630798

Group type: EXPERIMENTAL
Intervention: Spinal-epidural anesthesia with intravenous injection of dexmedetomidine
Number of subjects: 100

Group type: COMPARATOR
Intervention: General anesthesia (Control group)
Number of subjects: 100
Study: 27117038

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 127
Study: 24521108

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 719

Group type: COMPARATOR
Intervention: Pramipexole 0.5 mg
Number of subjects: 719

Group type: COMPARATOR
Intervention: Pramipexole 0.25 mg
Number of subjects: 719

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 719
Study: 23525418

Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 6983

Group type: EXPERIMENTAL
Intervention: Warfarin therapy (experienced vs naïve)
Number of subjects: 6983

Group type: EXPERIMENTAL
Intervention: Geographic region
Number of subjects: 6983
Study: 20597245

Group type: EXPERIMENTAL
Intervention: Nicotine gum (4 mg, one stick per hour)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 29

Group type: COMPARATOR
Intervention: No cigarettes/no gum
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nicotine cigarettes
Number of subjects: 29
Study: 19075486

Group type: EXPERIMENTAL
Intervention: Orthostatic training (64 patients)
Number of subjects: 125

Group type: COMPARATOR
Intervention: No treatment (controls, 61 patients)
Number of subjects: 125
Study: 16636023

Group type: EXPERIMENTAL
Intervention: Allowing wounds to be uncovered and wet in the first 48 hours (n = 415)
Number of subjects: 857

Group type: COMPARATOR
Intervention: Standard management of keeping wounds dry and covered (n = 442)
Number of subjects: 857
Study: 12851527

Group type: EXPERIMENTAL
Intervention: Intensive cardiovascular risk factor management for 6 months
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Flow-mediated dilatation (FMD)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Plasma von Willebrand factor (vWF)
Number of subjects: 132
Study: 11099628

Group type: EXPERIMENTAL
Intervention: Cisapride (0.80 mg/kg/day for group 1 and 2; 0.72 mg/kg/day for group 3)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control (no cisapride)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 252
Study: 7841817

Group type: COMPARATOR
Intervention: Gamma Knife capsulotomy
Number of subjects: 0
Study: 2830968

Group type: EXPERIMENTAL
Intervention: Thymosin fraction V (60 mg/m2 s.c. twice weekly) during induction chemotherapy and radiation therapy
Number of subjects: 91

Group type: COMPARATOR
Intervention: No thymosin
Number of subjects: 91
Study: 31515562

Group type: EXPERIMENTAL
Intervention: Serum neurofilament light chain (sNfL) levels measured using an ultrasensitive single‐molecule array assay (Simoa)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Presymptomatic sNfL levels
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Postonset sNfL levels
Number of subjects: 60
Study: 28592218

Group type: EXPERIMENTAL
Intervention: Contact aspiration
Number of subjects: 380

Group type: COMPARATOR
Intervention: Stent retriever
Number of subjects: 380
Study: 28463718

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive remediation (CACR) therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 33
Study: 28129987

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus capecitabine
Number of subjects: 732

Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 732
Study: 23953136

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 390
Study: 20538494

Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 19397113

Group type: EXPERIMENTAL
Intervention: Non-radiographic method of measuring knee alignment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiographic method of measuring knee alignment
Number of subjects: 0
Study: 17885293

Group type: EXPERIMENTAL
Intervention: ANRS GIS
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: DMC GIS
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: REGA GIS
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Stanford GIS
Number of subjects: 744
Study: 15841581

Group type: EXPERIMENTAL
Intervention: Surgical stent for bone reduction
Number of subjects: 10

Group type: COMPARATOR
Intervention: No surgical stent (control group)
Number of subjects: 10
Study: 11765387

Group type: EXPERIMENTAL
Intervention: Antenatal education programme for couples (clinic-based)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based antenatal education programmes for expectant fathers
Number of subjects: 0
Study: 9759796

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.01%
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.05%
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1%
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.15%
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 7882486

Group type: EXPERIMENTAL
Intervention: 115-J (70-microF) biphasic pulse
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 130-J (105-microF) biphasic pulse
Number of subjects: 30

Group type: COMPARATOR
Intervention: 200-J (36-microF, 28-mH) damped sine wave pulse
Number of subjects: 30
Study: 2164477

Group type: EXPERIMENTAL
Intervention: Propranolol (non-selective beta-blocker)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metoprolol (beta 1-selective blocker)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 10
Study: 371649

Group type: EXPERIMENTAL
Intervention: Controlled ventilation with halothane
Number of subjects: 100

Group type: COMPARATOR
Intervention: Controlled ventilation with fentanyl
Number of subjects: 100
Study: 31937915

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) - 10×1-min intervals at 90-100% peak workload, 3 times per week for 6 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT) - 30 min at 65-75% peak heart rate, 3 times per week for 6 weeks
Number of subjects: 28
Study: 28277432

Group type: EXPERIMENTAL
Intervention: Hypoxia (FiO2 ∼14.8%)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 8
Study: 27486198

Group type: EXPERIMENTAL
Intervention: Culturally tailored Internet Cancer Support Group (ICSG)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 25991461

Group type: EXPERIMENTAL
Intervention: Wraparound care initiated at the time of their visit for injury due to violence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 23706259

Group type: EXPERIMENTAL
Intervention: Antibiotic group (flomoxef sodium every 12 hours for 3 days)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Non‐postoperative antibiotic group
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Antibiotic group
Number of subjects: 241
Study: 21744744

Group type: EXPERIMENTAL
Intervention: Myo-inositol (2 g) + Folic acid (200 microg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Folic acid (200 microg)
Number of subjects: 0
Study: 19560195

Group type: EXPERIMENTAL
Intervention: Powder-liquid opaquer (Sinfony, 3M ESPE) at 0.25 mm thickness
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Powder-liquid opaquer (Sinfony, 3M ESPE) at 0.50 mm thickness
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Paste opaquer (Cimara, Voco) at 0.25 mm thickness
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Paste opaquer (Monopaque, Ivoclar Vivadent) at 0.25 mm thickness
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Paste opaquer (Monopaque, Ivoclar Vivadent) at 0.50 mm thickness
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Paste opaquer (Cavex Experimental, Cavex) at 0.25 mm thickness
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Paste opaquer (Cavex Experimental, Cavex) at 0.50 mm thickness
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All opaquers
Number of subjects: 80
Study: 16671489

Group type: EXPERIMENTAL
Intervention: Ventriculoperitoneal shunt with gravitational valve
Number of subjects: 51
Study: 15289800

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sildenafil 50 mg
Number of subjects: 28
Study: 11559340

Group type: EXPERIMENTAL
Intervention: Topical nasal drops dyed with methylene blue (0.1% v/v)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical aqueous sprays dyed with methylene blue (0.1% v/v)
Number of subjects: 0
Study: 9427455

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (Pa)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Whole cell pertussis vaccine (Pw)
Number of subjects: 201
Study: 7705531

Group type: EXPERIMENTAL
Intervention: Low-dose monophasic pill
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High-dose monophasic pill
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Multiphasic pill
Number of subjects: 80

Group type: COMPARATOR
Intervention: No therapy (expectant management)
Number of subjects: 80
Study: 2884705

Group type: EXPERIMENTAL
Intervention: 4 mg tulobuterol/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 7.5 mg fenoterol/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inhalative fenoterol
Number of subjects: 10

Group type: COMPARATOR
Intervention: No treatment / pretreatment with oral fenoterol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tulobuterol and fenoterol treatment
Number of subjects: 10
Study: 30123970

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 15 mg BID plus regorafenib 160 mg QD
Number of subjects: 396

Group type: COMPARATOR
Intervention: Placebo plus regorafenib 160 mg QD
Number of subjects: 396
Study: 27607858

Group type: EXPERIMENTAL
Intervention: Midurethral sling
Number of subjects: 113

Group type: COMPARATOR
Intervention: Burch retropubic urethropexy
Number of subjects: 113
Study: 24771634

Group type: EXPERIMENTAL
Intervention: 2 g ceftriaxone (IV infusion every 12 hours)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (IV infusion every 12 hours)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 2 g ceftriaxone twice (IV infusion every 12 hours)
Number of subjects: 66
Study: 22698562

Group type: EXPERIMENTAL
Intervention: Right ventricle-to-pulmonary artery shunt
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Modified Blalock-Taussig shunt
Number of subjects: 546

Group type: COMPARATOR
Intervention: Local standard of care
Number of subjects: 546
Study: 20307829

Group type: EXPERIMENTAL
Intervention: Plain packaging with varying degrees of brand elements removed and increased size of pictorial health warnings (30% to 80%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plain packaging with increased size of pictorial health warnings
Number of subjects: 0
Study: 18435883

Group type: EXPERIMENTAL
Intervention: Topical rifamycin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no rifamycin treatment)
Number of subjects: 48
Study: 16163871

Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1
Number of subjects: 9

Group type: COMPARATOR
Intervention: Scotchbond Multipurpose
Number of subjects: 9
Study: 12966123

Group type: EXPERIMENTAL
Intervention: Vigorous intensity/high duration
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Moderate intensity/high duration
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Moderate intensity/moderate duration
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Vigorous intensity/moderate duration
Number of subjects: 201
Study: 11525344

Group type: EXPERIMENTAL
Intervention: Preparing for the Drug‐Free Years (PDFY) curriculum
Number of subjects: 424

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 424
Study: 8806290

Group type: EXPERIMENTAL
Intervention: Co-amoxiclav suspension (20 mg/kg amoxicillin, 5 mg/kg clavulanate potassium), orally three times a day for 14 days
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 1352828

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Terazosin
Number of subjects: 40
Study: 6371693

Group type: EXPERIMENTAL
Intervention: Ritodrine (max dose, 350 mcg/min intravenously for 12 hours, then 20 mg orally every 4 hours)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (intravenously for 12 hours, then oral therapy)
Number of subjects: 35
Study: 30935906

Group type: EXPERIMENTAL
Intervention: Online teaching with typical pictures and APLOC definitions (Group A)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Definitions only (Group B)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Experts
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Group A (ulceration)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Group B (ulceration)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Group A (fistulae)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Group B (fistulae)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Group A (erythema)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Group B (erythema)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Group A (anoperineal scars)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Group B (anoperineal scars)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Group A (abscess)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Group B (abscess)
Number of subjects: 248
Study: 30021759

Group type: EXPERIMENTAL
Intervention: High phosphate diet (regular diet plus 1 mmol/kg body wt per day of Na as neutral sodium phosphate)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High phosphate diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low phosphate diet (regular diet plus lanthanum, 750 mg thrice/day, plus 0.7 mmol/kg body wt per day of Na as NaCl)
Number of subjects: 20
Study: 27320828

Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sham Taping
Number of subjects: 76
Study: 24577847

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy delivered by lay providers (BLP), n = 76
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy delivered by Ph.D.-level expert providers (PLP), n = 74
Number of subjects: 223

Group type: COMPARATOR
Intervention: Usual care (UC), n = 73
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy delivered by lay providers (BLP)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy delivered by Ph.D.-level expert providers (PLP)
Number of subjects: 223
Study: 22943664

Group type: EXPERIMENTAL
Intervention: Endometrial biopsy using a pipelle curette on days 9‐12 and 21‐24 of the menstrual cycle preceding IVF treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cervical pipelle performed (Control)
Number of subjects: 36
Study: 19322797

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 81
Study: 17405883

Group type: EXPERIMENTAL
Intervention: Afferent stimulation combined with task-specific training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation (Control)
Number of subjects: 20
Study: 15056575

Group type: EXPERIMENTAL
Intervention: Cognitive therapy for command hallucinations (CTCH)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 38
Study: 11466749

Group type: EXPERIMENTAL
Intervention: Multifaceted secondary prevention intervention including training sessions for caregivers, information sessions for personnel, residents, and relatives, and group interventions.
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: High GDS scoring participants from the intervention group.
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group (211 residents from matched residential homes).
Number of subjects: 213
Study: 9683362

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g six times a day during radiotherapy)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 102
Study: 7530379

Group type: EXPERIMENTAL
Intervention: Risperidone (4 mg dose in caplet form)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Risperidone (4 mg dose in tablet form)
Number of subjects: 24
Study: 3346865

Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metronidazole 1500 mg
Number of subjects: 20
Study: 28595236

Group type: EXPERIMENTAL
Intervention: Nonlinear Resistance Training (NRT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 33
Study: 27649258

Group type: EXPERIMENTAL
Intervention: Monoblock polyethylene insert
Number of subjects: 53

Group type: COMPARATOR
Intervention: Modular polyethylene insert
Number of subjects: 53
Study: 25217488

Group type: EXPERIMENTAL
Intervention: Velocity ratio (VR) <0.25
Number of subjects: 435

Group type: COMPARATOR
Intervention: Velocity ratio (VR) >0.25
Number of subjects: 435

Group type: COMPARATOR
Intervention: Mean pressure gradient (MPG)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Velocity ratio (VR)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Adjusted aortic valve area (AVA) by VR
Number of subjects: 435
Study: 22819386

Group type: EXPERIMENTAL
Intervention: Pharmacist-initiated medication reconciliation
Number of subjects: 218

Group type: COMPARATOR
Intervention: Physician-initiated medication reconciliation
Number of subjects: 218
Study: 20715595

Group type: EXPERIMENTAL
Intervention: 400 mg/day of algal DHA
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1094
Study: 18846487

Group type: EXPERIMENTAL
Intervention: Cruciate-sacrificing NexGen Full Flex implant
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cruciate-retaining CKS-CC knee system
Number of subjects: 44
Study: 16838494

Group type: EXPERIMENTAL
Intervention: Zwislocki-type adaptive procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levitt-type adaptive procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both adaptive procedures
Number of subjects: 0
Study: 12813340

Group type: EXPERIMENTAL
Intervention: Early movement of the ankle between neutral and plantar flexion in a brace for 6 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Achilles tendon immobilization in tension using a below‐knee cast with the ankle in a neutral position for 6 weeks
Number of subjects: 50
Study: 10590505

Group type: EXPERIMENTAL
Intervention: Rhythm control and anticoagulation
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Rate control and anticoagulation
Number of subjects: 3000
Study: 9012115

Group type: EXPERIMENTAL
Intervention: Iodine (100 micrograms iodide)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Selenium (50 micrograms selenium)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Combination of iodine and selenium
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 88
Study: 1636917

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 20
Study: 6712366

Group type: EXPERIMENTAL
Intervention: Computer-assisted (CA) initial lidocaine hydrochloride therapy
Number of subjects: 156

Group type: COMPARATOR
Intervention: Conventional lidocaine therapy (CT)
Number of subjects: 156
Study: 30879006

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Number of subjects: 260

Group type: COMPARATOR
Intervention: Fluticasone propionate
Number of subjects: 260
Study: 29884676

Group type: EXPERIMENTAL
Intervention: Baseline tryptophan
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Positive changes in quinolinic acid from baseline to 1 year
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Baseline tryptophan and kynurenic acid
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Concurrent changes in kynurenine, quinolinic acid, 3‐hydroxyanthranilic acid, and kynurenine/tryptophan ratio
Number of subjects: 641
Study: 26341357

Group type: EXPERIMENTAL
Intervention: Enhanced Behavioral Treatment (EBT)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard Behavioral Treatment (SBT)
Number of subjects: 79
Study: 24732629

Group type: EXPERIMENTAL
Intervention: Baseline plasma vitamin D (25-hydroxy) concentration
Number of subjects: 1731

Group type: EXPERIMENTAL
Intervention: Higher vitamin D levels
Number of subjects: 1731
Study: 22865603

Group type: EXPERIMENTAL
Intervention: Low Carbohydrates Diet
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Low Fat Diet
Number of subjects: 305
Study: 20378050

Group type: EXPERIMENTAL
Intervention: Active plant metabolites (e.g., flavonoids, terpenoids, glycosides) as digestive enzyme inhibitors; specific dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Currently used digestive enzyme inhibitors (bacterial secondary metabolites); specific dosage and duration not available.
Number of subjects: 0
Study: 18049291

Group type: EXPERIMENTAL
Intervention: Stacking multiple intervention components (child-based program, parent training program, teacher-based program)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Single intervention components (child-based program, parent training program, teacher-based program)
Number of subjects: 459
Study: 16754441

Group type: EXPERIMENTAL
Intervention: PolyHeme®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blood
Number of subjects: 0
Study: 14602215

Group type: EXPERIMENTAL
Intervention: Tepid blood cardioplegia (CP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia (CP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100